What is the PCAC? The advisory committee between peptides and FDA approval

If you buy peptides today, you buy them from a research-chemical site. A vial labelled not for human consumption. No prescription, no pharmacist, no doctor anywhere in the transaction. The distance between that and a peptide a US pharmacy can legally make you comes down to a committee almost nobody has heard of. It sits for two days, votes on twelve compounds, and its recommendations will shape whether any of them ever get a legitimate supply chain.

It’s called the PCAC — the Pharmacy Compounding Advisory Committee. Here’s what it is, what it’s about to decide, and what its vote does and doesn’t mean for the peptide you’re tracking.

What the PCAC actually is

The PCAC is a standing FDA advisory panel with one job: tell the agency which substances belong on the Section 503A bulk drug substances list. Section 503A is the corner of federal law that governs traditional pharmacy compounding — where a licensed pharmacist makes a drug to fill a prescription for a named patient when no approved product fits the need.

The word that carries the weight is advisory. The committee doesn’t approve drugs and doesn’t write rules. It reviews a nomination, takes public comment, and recommends a position. The FDA then makes the real decision later, through formal rulemaking. The vote is the signal the agency uses to write the rule — not the rule itself.

What makes it matter now is the line-up. The panel is being handed a batch of peptides — twelve of them, across two meetings, nearly all sold off-label through research-chemical vendors right now. Its recommendations will help decide whether those compounds ever become something a US doctor can prescribe and a licensed pharmacy can make.

The two meetings, and what’s on them

The April 2026 Federal Register notice 2026-07361 sets the agenda. Two waves.

The first runs July 23–24, 2026, at the FDA’s White Oak campus in Silver Spring, Maryland. Seven peptides, split across the two days, each attached to a specific FDA-reviewed indication:

• July 23 — BPC-157 (reviewed for ulcerative colitis), KPV (wound healing and inflammatory conditions), TB-500 (wound healing), and MOTs-C (obesity and osteoporosis).
• July 24 — Emideltide, better known as delta sleep-inducing peptide or DSIP (opioid withdrawal, chronic insomnia, and narcolepsy), Semax (cerebral ischemia, migraine, and trigeminal neuralgia), and Epitalon (insomnia).

Read those indications twice. They are not what the off-label market sells these compounds for. MOTs-C is reviewed for obesity, not longevity. Epitalon for insomnia, not telomere maintenance. Several sit at a right angle to the pitch the buyer has actually seen.

The second wave is scheduled before the end of February 2027 — the exact date isn’t published yet — for five more substances: Dihexa acetate, LL-37, GHK-Cu, PEG-MGF, and Melanotan II.

GHK-Cu is worth one flag, because it’s the sharpest illustration of how much the route of administration matters. The FDA split it in two. Injectable GHK-Cu — the form the off-label market actually sells — came off Category 2, the do not compound list. Topical GHK-Cu went the other direction: it was pulled off Category 1, the under evaluation list that had let pharmacies compound it under enforcement discretion, so the cream lost a safe harbor it used to have. Both forms go to the February meeting. The live question is about the injection.

What the vote does — and doesn’t — establish

This is the part forum coverage almost always flattens. A favourable PCAC recommendation is not an FDA approval. Not close.

The approval path for a marketed drug runs through Investigational New Drug applications, human trials in three phases, and a New Drug Application. None of that has been done for any of the twelve peptides on these dockets, and none of it will be finished by 2027.

What a favourable vote does is narrower, and still real: it clears the way for the substance to be dispensed in a compounded prescription by a US-licensed pharmacy, under Section 503A, for the exact indication the committee reviewed. A compounded BPC-157 script for ulcerative colitis would stand on a clear regulatory floor. The same script for a torn shoulder would be off-label use of a compounded drug — a greyer call the supervising physician has to make. The uses driving most of the demand sit outside what the committee actually voted on.

An unfavourable vote runs the other way. The FDA rarely lists a compound its own committee has recommended against, so a no can quietly close the compounding lane for years. Some of these peptides have already walked through that door and lost the vote.

What this means for your access

Strip out the procedure and the shape is simple. Right now the supply chain for all twelve peptides runs through research-chemical sites: vials marked not for human consumption, no third-party testing, no prescription, no physician. The PCAC review is the formal gate between that and a different supply chain — a US doctor’s prescription, a licensed compounding pharmacy, a named indication on the label, an assay on every batch.

A favourable vote followed by favourable FDA rulemaking opens that second chain for the indications under review. An unfavourable one leaves you exactly where you sit today. July is the first hard signal on which way the agency leans across the whole group.

So if you take one of these, the question was never will it get approved. It’s narrower and more useful. After July, after February, or not at all — will your doctor be able to write you a prescription a real pharmacy can fill? What actually happens after the vote is its own timeline, and it moves slower than the forums think.

Where this is heading

The honest read is cautious optimism. For the first time, the legitimate version of a market that has run underground for a decade is on an FDA calendar with a date attached to it. That’s not approval. It isn’t certainty. It’s the door being walked toward, in the open, on the record.

Wolverine Health is being built for the moment it opens — physician-supervised protocols, US-licensed compounding, every batch third-party tested. Leave your email and we’ll tell you the day the pathway turns real for the peptide you’re watching.